James ND, Tannock I, N’Dow J et al (2024) The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 403(10437):1683–1722. https://doi.org/10.1016/S0140-6736(24)00651-2. Epub 2024 Apr 4. Erratum in: Lancet. 2024;403(10437):1634. PMID: 38583453

Bergengren O, Pekala KR, Matsoukas K et al (2023) Update on prostate cancer epidemiology and risk Factors-A systematic review. Eur Urol 84(2):191–206. https://doi.org/10.1016/j.eururo.2023.04.021Epub 2023 May 16. PMID: 37202314

Article  PubMed  PubMed Central  Google Scholar 

Loeb S, Bjurlin MA, Nicholson J et al (2014) Overdiagnosis and overtreatment of prostate cancer. Eur Urol 65(6):1046–1055. https://doi.org/10.1016/j.eururo.2013.12.062

Article  PubMed  PubMed Central  Google Scholar 

Beyer K, Leenen R, Venderbos LDF et al (2024) Health policy for prostate cancer early detection in the European union and the impact of opportunistic screening: PRAISE-U consortium. J Pers Med 14(1):84. https://doi.org/10.3390/jpm14010084PMID: 38248785; PMCID: PMC10819943

Article  PubMed  PubMed Central  Google Scholar 

Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J (2015) Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. Eur Urol 68(3):354–360 Epub 2014 Dec 31. PMID: 25556937

PubMed  Google Scholar 

Hugosson J, Roobol MJ, Månsson M et al (2019) A 16-yr Follow-up of the European randomized study of screening for prostate cancer. Eur Urol 76(1):43–51. https://doi.org/10.1016/j.eururo.2019.02.009Epub 2019 Feb 26. PMID: 30824296; PMCID: PMC7513694

Article  PubMed  PubMed Central  Google Scholar 

de Vos II, Meertens A, Hogenhout R, Remmers S, Roobol MJ, ERSPC Rotterdam Study Group (2023) A detailed evaluation of the effect of prostate-specific Antigen-based screening on morbidity and mortality of prostate cancer: 21-year Follow-up results of the Rotterdam section of the European randomised study of screening for prostate cancer. Eur Urol 84(4):426–434 Epub 2023 Apr 5. PMID: 37029074

PubMed  Google Scholar 

McClintock TR, Cone EB, Marchese M et al (2020) Prostate cancer management costs vary by disease stage at presentation. Prostate Cancer Prostatic Dis 23(4):564–566. https://doi.org/10.1038/s41391-020-0239-xEpub 2020 May 14. PMID: 32409730

Article  PubMed  Google Scholar 

Desai MM, Cacciamani GE, Gill K et al (2022) Trends in incidence of metastatic prostate cancer in the US. JAMA Netw Open 5(3):e222246. https://doi.org/10.1001/jamanetworkopen.2022.2246PMID: 35285916; PMCID: PMC9907338

Article  PubMed  PubMed Central  Google Scholar 

de la Calle CM, Fasulo V, Cowan JE et al (2021) Clinical utility of 4Kscore®, exosomedx™ and magnetic resonance imaging for the early detection of high grade prostate cancer. J Urol 205(2):452–460. https://doi.org/10.1097/JU.0000000000001361

Article  PubMed  Google Scholar 

Vynckier P, Annemans L, Raes S et al (2024) Systematic review on the cost effectiveness of prostate cancer screening in Europe. Eur Urol Published Online May 23. https://doi.org/10.1016/j.eururo.2024.04.036

Agnello L, Vidali M, Giglio RV et al (2022) Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med 60(8):1261–1277 Published 2022 May 16. https://doi.org/10.1515/cclm-2022-0354

Article  CAS  PubMed  Google Scholar 

Ferro M, De Cobelli O, Lucarelli G et al (2020) Beyond PSA: the role of prostate health index (phi). Int J Mol Sci 21:1184. https://doi.org/10.3390/ijms21041184

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drummond MF, Sculpher MJ, Torrance GW et al (2005) Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford, p 404

Google Scholar 

Gross MD, Alshak MN, Shoag JE et al (2019) Healthcare costs of Post-Prostate biopsy sepsis. Urology 133:11–15. https://doi.org/10.1016/j.urology.2019.06.011Epub 2019 Jun 21. PMID: 31229516

Article  PubMed  Google Scholar 

Rius Bilbao L, Valladares Gomez C, Aguirre Larracoechea U et al (2023) Do PHI and PHI density improve detection of clinically significant prostate cancer only in the PSA Gray zone? Clin Chim Acta 542:117270. https://doi.org/10.1016/j.cca.2023.117270

Article  CAS  PubMed  Google Scholar 

Semjonow A, Köpke T, Eltze E, Pepping-Schefers B, Bürgel H, Darte C (2010) Pre-analytical in-vitro stability of [-2]proPSA in blood and serum. Clin Biochem 43(10–11):926–928. https://doi.org/10.1016/j.clinbiochem.2010.04.062

Article  CAS  PubMed  Google Scholar 

Lazzeri M, Haese A, de la Taille A et al (2013) Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 Ng/mL: a multicentric European study. Eur Urol 63:986–994

CAS  PubMed  Google Scholar 

Loeb S, Sanda MG, Broyles DL et al (2015) The prostate health index (phi) selectively identifies clinically-significant prostate cancer. J Urol 193:1163–1169

PubMed  Google Scholar 

Nordström T, Vickers A, Assel M et al (2015) Comparison between the four- Kallikrein panel and prostate health index for predicting prostate cancer. Eur Urol 68:139–146

PubMed  Google Scholar 

Garrido MM, Marta JC, Bernardino RM et al (2022) The percentage of [-2]Pro-Prostate-Specific antigen and the prostate health index outperform prostate-Specific antigen and the percentage of free prostate- specific antigen in the detection of clinically significant prostate cancer and can be used as reflex tests. Arch Pathol Lab Med 146(6):691–700

CAS  PubMed  Google Scholar 

Auvinen A, Tammela TLJ, Mirtti T et al (2024) ProScreen trial investigators. Prostate cancer screening with PSA, Kallikrein panel, and MRI: the proscreen randomized trial. JAMA 331(17):1452–1459. https://doi.org/10.1001/jama.2024.3841PMID: 38581254; PMCID: PMC10999002

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nordström T, Annerstedt M, Glaessgen A et al (2024) Repeated prostate cancer screening using prostate-Specific antigen testing and magnetic resonance imaging: A secondary analysis of the STHLM3-MRI randomized clinical trial. JAMA Netw Open 7(2):e2354577. https://doi.org/10.1001/jamanetworkopen.2023.54577PMID: 38324313; PMCID: PMC10851096

Article  PubMed  PubMed Central  Google Scholar 

Würnschimmel C, Chandrasekar T, Hahn L, Esen T, Shariat SF, Tilki D (2023) MRI as a screening tool for prostate cancer: current evidence and future challenges. World J Urol 41(4):921–928. https://doi.org/10.1007/s00345-022-03947-yEpub 2022 Feb 28. PMID: 35226140; PMCID: PMC10160206

Article  PubMed  Google Scholar 

Asif A, Nathan A, Ng A et al (2023) Comparing biparametric to multiparametric MRI in the diagnosis of clinically significant prostate cancer in biopsy-naive men (PRIME): a prospective, international, multicentre, non-inferiority within-patient, diagnostic yield trial protocol. BMJ Open 13(4):e070280. https://doi.org/10.1136/bmjopen-2022-070280PMID: 37019486; PMCID: PMC10083803

Article  PubMed  PubMed Central  Google Scholar 

Van Calster B, McLernon DJ, van Smeden M, Wynants L, Steyerberg EW (2019) Topic Group ‘Evaluating diagnostic tests and prediction models’ of the STRATOS initiative. Calibration: the Achilles heel of predictive analytics. BMC Med. 17(1):230. Published 2019 Dec 16. https://doi.org/10.1186/s12916-019-1466-

Remmers S, Kasivisvanathan V, Verbeek JFM, Moore CM, Roobol MJ, ERSPC Rotterdam Study Group PRECISION Investigators Group (2021) Reducing biopsies and magnetic resonance imaging scans during the diagnostic pathway of prostate cancer: applying the Rotterdam prostate cancer risk calculator to the PRECISION trial data. Eur Urol Open Sci 36:1–8 Published 2021 Dec 15. https://doi.org/10.1016/j.euros.2021.11.002

Article  PubMed  PubMed Central  Google Scholar 

Davik P, Remmers S, Elschot M, Roobol MJ, Bathen TF, Bertilsson H (2022) Reducing prostate biopsies and magnetic resonance imaging with prostate cancer risk stratification. BJUI Compass 3(5):344–353 Published 2022 Apr 22. https://doi.org/10.1002/bco2.146

Article  PubMed  PubMed Central  Google Scholar 

Foley RW, Maweni RM, Gorman L et al (2016) European randomised study of screening for prostate cancer (ERSPC) risk calculators significantly outperform the prostate cancer prevention trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study. BJU Int 118(5):706–713. https://doi.org/10.1111/bju.13437

Article  PubMed  Google Scholar 

Loeb S, Shin SS, Broyles DL et al (2017) Prostate health index improves multivariable risk prediction of aggressive prostate cancer. BJU Int 120(1):61–68. https://doi.org/10.1111/bju.13676

Article  CAS  PubMed  Google Scholar 

Nichol MB, Wu J, Huang J, Denham D, Frencher SK, Jacobsen SJ (2012) Cost-effectiveness of Prostate Health Index for prostate cancer detection. BJU Int. 110(3):353 – 62. https://doi.org/10.1111/j.1464-410X.2011.10751.x. Epub 2011 Nov 11. PMID: 22077934

Heijnsdijk EA, Denham D, de Koning HJ (2016) The cost-effectiveness of prostate cancer detection with the use of prostate health index. Value Health 19:153–157

PubMed  Google Scholar 

García-Mochón L, Špacírová Z, Espín J (2022) Costing methodologies in European economic evaluation guidelines: commonalities and divergences. Eur J Health Econ 23(6):979–991. https://doi.org/10.1007/s10198-021-01414-wEpub 2021 Nov 26. PMID: 34825296

Article  PubMed  Google Scholar